Every year about 34.5 million chronic wounds are treated globally. Kerecis is committed to the prevention and treatment of chronic wounds - that often are the consequence of diabetes and circulation complications. Chronic wounds cause patients severe emotional and physical stress and create a significant financial burden on patients and the whole healthcare system. In the chronic wound the balance between production and degradation of molecules such as collagen is lost and degradation plays too large a role. Kerecis provides a unique solution that helps the wound regain balance and heal.

KERECIS OFFERS PRODUCTS THAT PREVENT AND TREAT CHRONIC WOUNDS

MariCell™ Intensive Foot Repair Cream is the most advanced product in the Kerecis development pipeline. Market tests will start late 2010 and market launch is estimated in Q3, 2011. The product is a patent-pending, quad-action formula especially developed to improve the health of the diabetic foot. The product helps maintain and repair the outermost layer of the skin, hydrates the skin, reduces and softens callosities and minimizes skin cracking and wound formation

Every year 34.5 million chronic wounds are treated globally. Chronic wounds are those that get stuck in the inflammatory stage and do not heal. Chronic wounds cause patients severe emotional and physical stress and create a significant financial burden on patients and the whole healthcare system. In the chronic wound the balance between production and degradation of molecules such as collagen is lost and degradation plays too large a role. Kerecis provides a unique solution that helps the wound regain balance and heal.